Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with ...

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

Telix Pharmaceuticals has reported further "encouraging" results from its brain cancer radiotherapy program. ... Read More ...

Radiotherapy uses high energy waves, similar to x-rays, to kill cancer cells. You usually have external beam radiotherapy for stomach cancer. External beam radiotherapy directs radiotherapy beams at ...

Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.

Your doctor will discuss with you how many sessions you need. Before you begin your treatment, the radiotherapy team carefully plan your external beam radiotherapy. This means working out how much ...

IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam ...

Telix Pharmaceuticals Limited, today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent ...